Full Press Release Details
Changing the Shape of Medical Research and Practice
Chairman and Chief Executive Officer
Copyright 2013, Organovo Holdings, Inc. This report is solely for the use of intended audience. No part of it may be circulated, quoted, or reproduced for distribution outside the organization without prior written approval from Organovo Holdings,
SAFE HARBOR STATEMENT
Any statements contained in
this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements are based on our current expectations,
but are subject to a number of risksand uncertainties. The factors that could cause our actual future results to differ materially from our current expectations include, but are not limited to, risks and uncertainties relating to the Company s
ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company s products and technology; the availability of substantial additional funding to support the Company s operations; the
Company s ability to enter into successful collaboration arrangements; and the Company s ability to achieve its business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other
factors are identified and described in more detail in our filings with the SEC, including our annual report on Form 10-K filed with the SEC on March 15, 2013. You should not place undue reliance on forward-looking statements, which speak only
as of the date of this presentation. Except as required by applicable law, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the
occurrence of unanticipated events.
Changing the shape of medical research and practice
Copyright 2012 Organovo Holdings, Inc.
Organovo holds rights to proprietary bio-printing technology developed at the University of Missouri with a $5M National Science Foundation grant
Based in San Diego in a 15,000 sq ft facility with dedicated bioprinting / tissue culture and analytical laboratories
A leader in 3D printing of human tissue targeting in vitro and in vivo applications
Copyright 2013 Organovo, Inc.
Changing the shape of medical research and practice
Changing the shape of medical research and practice
Copyright 2013 Organovo Holdings, Inc.3
Organovo s pioneering technology creates functional human tissues without scaffolds
Changing the shape of medical research and practice
Tissue sheets, branched tubes, and layered tubes have been bioprinted
(A) Bio-ink composed of chick cardiac cell aggregates; (B) Bio-ink composed of CHO cells; (C) A bi-layered tube composed of fibroblasts and smooth muscle cells (brown = smooth
muscle actin). Adapted from Biofabrication 2:1, 2010, coauthored by K. Murphy and G. Forgacs, ONVO s CEO and Scientific Founder.
Copyright 2013 Organovo Holdings, Inc.5
Changing the shape of medical research and practice
Drug discovery: There is an imperative for pharmacos to kill drugs faster and cheaper
Copyright 2013 Organovo Holdings, Inc.
Changing the shape of medical research and practice
Market research reveals opportunity
Identified specific market opportunity >$500M by 2018
High unmet customer need and market opportunity identified that can be met with 3D cell assay products
Overall cell biology market growing to $17B by 2016, 12% CAGR
Disease models Source: 2012 Scientia Advisors market research, sponsored by company
Qualitative market research conducted to target initial opportunities including Oncology
Focus on Pharma co. lead optimization as entry point
Copyright 2013 Organovo Holdings, Inc.
Changing the shape of medical research and practice
We have partnered with corporate and academic partners to develop 3D tissues
Copyright 2013 Organovo, Inc.
shape of medical research and practice
Academic Partnership in Drug Discovery
Cancer research top investigators (Gleevec, FISH)
Allows Organovo to move upstream in discovery efforts
Copyright 2013 Organovo Holdings, Inc.
Changing the shape of medical research and practice
Organovo s opportunities reach beyond pharma
Bioprinted surgical tissues
Heart muscles Renal patches
Livers Lungs Kidneys
Organovo Holdings, Inc.
Changing the shape of medical research and practice
Organovo has made tremendous progress
Successfully hit targets in Pfizer collaboration
Expanded contract with United Therapeutics
Autodesk & ZenBio partnerships
15,000 sq. ft. new facility
Completed initial market research
Copyright 2013 Organovo Holdings, Inc.
Changing the shape of medical research and practice
Autodesk Partnership
Develop 3D Bioprinting design software
Organovo will be engaging with technology partners that complement our core capabilities in 3D functional human tissues
End 2012 Cash on hand $14.8M
March 14 raised additional $2.3M
Copyright 2013 Organovo Holdings, Inc.
Changing the shape of medical research and practice
Organovo will keep delivering: 2013 Milestones
Major new data on 3D liver this month
Functional validation of 3D liver by Dec 2013
Initiate alpha testing with KOLs by Apr 2014
Liver assay launch by Dec 2014
Additional technology partnerships to develop bioprinting
Change in fiscal year to year end Mar 31
Continue make progress and stay on track for application for NYSE or NASDAQ uplisting by mid-year
Copyright 2013 Organovo Holdings, Inc.
Changing the shape of medical research and practice
Organovo s bioprinting technology
Accelerates breakthrough research
Better recreation of human biology in a petri dish
Better than animal models
Better than cells alone
Has broad applications for unmet needs
Pharma Drug Discovery (Now)
Toxicology Testing (Now)
Copyright 2013 Organovo Holdings, Inc.
Changing the shape of medical research and practice
KEITH MURPHY, CEO & President
19 years of experience in biotechnology
Amgen, 10 years, Global Operations Leader, Prolia/Xgeva
Alkermes, drug delivery technology background
UCLA, School of Business
BARRY MICHAELS, CFO & Secretary
30 years of financial and general management experience in medical device and biotechnology
CFO of three private and three publicly traded companies
Finalist, San Diego CFO of the Year for 2012
Copyright 2013 Organovo Holdings, Inc.
Changing the shape of medical research and practice